Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 133

Sort by

Sort Order Select

Journal Articles

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Eric Lowe, BS, Andrea R Fan, PhD, Jing Jiang, Henry W. B. Johnson, PhD, Christopher J. Kirk, PhD, Dustin McMinn, PhD, Tony Muchamuel, MS, Yu Qian, PhD, Brian B. Tuch, PhD

Blood (2019) 134 (Supplement_1): 408.

https://doi.org/10.1182/blood-2019-123782

Published: 2019

Journal Articles

The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism

Michael Heider, Ruth Eichner, Jacob Stroh, Anna Kuisl, Jana Zecha, Jannis Lawatscheck, Martina Rudelius, Anne-Kathrin Garz, Simone Lemeer, Christian Peschel, Ulrich Keller, MD, Katharina Götze, Johannes Buchner, Bernhard Kuster, Vanesa Fernandez-Saiz, Florian Bassermann, MD PhD

Blood (2019) 134 (Supplement_1): 314.

https://doi.org/10.1182/blood-2019-129064

Published: 2019

Journal Articles

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Fabian Freisleben, Hauke Stamm, PhD, Jana Muschhammer, Vanessa Thaden, Franziska Modemann, MD, Alexander Krispien, Franziska Brauneck, Jasmin Wellbrock, PhD, Walter Fiedler, MD

Blood (2019) 134 (Supplement_1): 5050.

https://doi.org/10.1182/blood-2019-129973

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Neil Beeharry, Sean Landrette, PhD, Jeff Grotzke, PhD, Sophia Gayle, PhD, Marylens Hernandez, PhD, Stephanie Halene, MD, Peter R Young, PhD, Langdon L Miller, MD, Tian Xu, PhD, Jonathan Rothberg, PhD, Henri Lichenstein, PhD

Blood (2019) 134 (Supplement_1): 2664.

https://doi.org/10.1182/blood-2019-125770

Published: 2019

Journal Articles

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Yu Qian, PhD, Henry W.B. Johnson, PhD, Christopher J. Kirk, PhD, Eric Lowe, BS, Dustin McMinn, PhD, Beatriz Millare, BS, Tony Muchamuel, MS, Jinhai Wang, PhD

Blood (2019) 134 (Supplement_1): 2076.

https://doi.org/10.1182/blood-2019-125988

Published: 2019

Journal Articles

Socially Excluded Persons in Ireland Have an Increased Annual Risk of Hospitalisation Due to Venous Thromboembolic Disease

Karl Ewins, Fionnuala Ni Ainle, PhD, Eoghan Dunlea, MB BCh MRCPI, Sarah Kelliher, MBBS, Vicky Sandys, MB BCh MRCPI, Hannorah Rooney, BM BCh MRCPI, Lily Macken, MB BCh MRCPI, Ni Cheallaigh Cliona, MB BCH MRCPI PhD

Blood (2019) 134 (Supplement_1): 4702.

https://doi.org/10.1182/blood-2019-130371

Published: 2019

Journal Articles

PML Mutation in PML-Rarα Alters PML Nuclear Body Organization and Induces ATRA Resistance in Acute Promyelocytic Leukemia

Hong-Hu Zhu, MD, Congying Wu, Yujie Sun, Jiong Hu, MD

Blood (2018) 132 (Supplement 1): 3923.

https://doi.org/10.1182/blood-2018-99-118310

Published: 2018

Journal Articles

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Andrei R. Shustov, MD, Amitkumar Mehta, MD, Lubomir Sokol, MD PhD, Luis A. Carvajal, PhD, Vincent Guerlavais, PhD, Manoj Samant, PhD, Narayana Narasimhan, PhD, David Sutton, BSc, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Ronald Korn, MD PhD

Blood (2018) 132 (Supplement 1): 5348.

https://doi.org/10.1182/blood-2018-99-119489

Published: 2018

Journal Articles

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Janani Ravikrishnan, BS, Tzung-Huei Lai, PhD, Shaneice Renee Mitchell, BS, Pei-Jung Wu, BS, Shelley Orwick, BS, Chaomei Liu, PhD, Jennifer A. Woyach, MD, Alice S. Mims, MD, William Plunkett, PhD, Vinay K Puduvalli, MD MBBS, John C. Byrd, MD, Rosa Lapalombella, PhD, Deepa Sampath, PhD

Blood (2018) 132 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2018-99-116485

Published: 2018

Journal Articles

Suppression of Cdc37 Induces BTZ Resistance through XBP1s Mediated Plasma Cell Immaturation in Multiple Myeloma

Meirong Zang, Lanting LIU, Fengyan Jin, Jiaojiao Guo, An Gang, MD, Xiaoqi Qin, Tao Zhu, Shuhui Deng, Zhang Shuaishuai, MD, Mu Hao, PhD, Xiaoyan Feng, Yan Xu, MD, Wen Zhou, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 4350.

https://doi.org/10.1182/blood.V130.Suppl_1.4350.4350

Published: 2017

Journal Articles

Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia

Hein Than, MD FRCPath, MRCP, Anthony D. Pomicter, MS, Clinton C. Mason, PhD, Anna M. Eiring, PhD, William L. Heaton, MS, Dongqing Yan, Anna Senina, MS, Phillip M. Clair, MS, Tessa L. Holyoake, MD PhD FRCP, FRCPath, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 42.

https://doi.org/10.1182/blood.V130.Suppl_1.42.42

Published: 2017

Journal Articles

HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas

Maria Nieves Calvo Vidal, PhD, Jan Krumsiek, PhD, Jayeshkumar Patel, MS, Shao Ning Yang, Jude M Phillip, DPhil, Rossella Marullo, MD PhD, Tony Taldone, PhD, Giorgio Inghirami, MD, Ari Melnick, MD, Gabriela Chiosis, PhD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 645.

https://doi.org/10.1182/blood.V130.Suppl_1.645.645

Published: 2017

Journal Articles

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

Sudhakiranmayi Kuravi, M.S., Elizabeth Parrott, M.A., Siddhartha Ganguly, MD, Anusha Vallurupalli, MD, Yogenthiran Saunthararajah, MD, Brian S Blagg, PhD, Jensen Roy, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2017) 130 (Supplement 1): 2758.

https://doi.org/10.1182/blood.V130.Suppl_1.2758.2758

Published: 2017

Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD

Blood (2016) 128 (22): 2827.

https://doi.org/10.1182/blood.V128.22.2827.2827

Published: 2016

Journal Articles

Development, Implementation, and Testing of a Web Based Decision Aid for Facilitating Shared Decision Making for Disease Modifying Therapies for Sickle Cell Disease

Lakshmanan Krishnamurti, MD, Diana Ross, MSN, RN, Nitya Bakshi, MBBS, MS, Kirshma Khemani, MD, Cynthia Sinha, PhD, George Loewenstein, PhD

Blood (2016) 128 (22): 5919.

https://doi.org/10.1182/blood.V128.22.5919.5919

Published: 2016

Journal Articles

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

Sudhakiranmayi Kuravi, M.S., Preethi Kunchala, M.S., Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Yogen Saunthararajah, MD, Kojo S. J. Elenitoba-Johnson, MD, Jensen Roy, MD, Joseph McGuirk, DO, Ramesh Balusu, PhD

Blood (2016) 128 (22): 4127.

https://doi.org/10.1182/blood.V128.22.4127.4127

Published: 2016

Journal Articles

Agent Orange Exposure Does Not Predict for Shorter Overall Survival in Patients with Chronic Lymphocytic Leukemia: A National Veteran Affairs Tumor Registry Study

Craig Mescher, MD, Nicole Randall, MD, Gobind Tarchand, Lisa M. Baumann Kreuziger, MD MS, Dave Gilbertson, Julie Tomaska, Vicki A. Morrison, MD

Blood (2016) 128 (22): 5568.

https://doi.org/10.1182/blood.V128.22.5568.5568

Published: 2016

Journal Articles

HSP90 Stabilizes B-Cell Receptor Kinases in a Multi-Client Interactome: PU-H71 Induces CLL Apoptosis in a Cytoprotective Microenvironment

Yue Lynn Wang, MD PhD, Pin Lu, PhD, Jimmy Lee, MD, Chao Jie Zhen, BS, Gabriela Chiosis, PhD, Ailin Guo, Ph DMD

Blood (2016) 128 (22): 5105.

https://doi.org/10.1182/blood.V128.22.5105.5105

Published: 2016

Journal Articles

A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML

Hongliang Zong, MD PhD, Tony Taldone, PhD, Gail J. Roboz, MD, Gabriela Chiosis, PhD, Monica L. Guzman, PhD

Blood (2015) 126 (23): 2567.

https://doi.org/10.1182/blood.V126.23.2567.2567

Published: 2015

NARROW

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Socially Excluded Persons in Ireland Have an Increased Annual Risk of Hospitalisation Due to Venous Thromboembolic Disease

PML Mutation in PML-Rarα Alters PML Nuclear Body Organization and Induces ATRA Resistance in Acute Promyelocytic Leukemia

Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Suppression of Cdc37 Induces BTZ Resistance through XBP1s Mediated Plasma Cell Immaturation in Multiple Myeloma

Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia

HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Development, Implementation, and Testing of a Web Based Decision Aid for Facilitating Shared Decision Making for Disease Modifying Therapies for Sickle Cell Disease

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

Agent Orange Exposure Does Not Predict for Shorter Overall Survival in Patients with Chronic Lymphocytic Leukemia: A National Veteran Affairs Tumor Registry Study

HSP90 Stabilizes B-Cell Receptor Kinases in a Multi-Client Interactome: PU-H71 Induces CLL Apoptosis in a Cytoprotective Microenvironment

A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only